External News Archive
In developed countries, aging is the ultimate cause of 90% of all human deaths; thus, treating aging is a form of preventive medicine for all of the diseases of old age. Moreover, even before aging leads to our death, it reduces our capacity to enjoy our own lives and to contribute positively to the lives of others. So, instead of targeting specific diseases that are much more likely to occur when people have reached a certain age, wouldn’t a better strategy be to attempt to forestall or repair the damage done to our bodies by the aging process?Read More at Should We Live to 1,000?.
Read More at http://www.news-medical.net/news/20120824/Scientists-develop-reliable-method-to-....
Johns Hopkins scientists have developed a reliable method to turn the clock back on blood cells, restoring them to a primitive stem cell state from which they can then develop into any other type of cell in the body.
Read More at http://www.nottingham.ac.uk/News/pressreleases/2012/july/taking-tissue-regenerat....
The University of Nottingham has begun the search for a new class of injectable materials that will stimulate stem cells to regenerate damaged tissue in degenerative and age related disorders of the bone, muscle and heart.
Read More at http://cirmresearch.blogspot.co.uk/2012/03/stem-cell-research-and-aging-symposiu....
The 2012 Buck Symposium on Stem Cell Research and Aging brought together some of the world’s cutting-edge researchers, but more importantly, it provided a space for the formal convergence of stem cell-based regenerative medicine and aging research.
Destructive plaques found in the brains of Alzheimer's patients have been rapidly cleared by researchers testing a cancer drug on mice.The US study, published in the journal Science, reported the plaques were broken down at "unprecedented" speed. Tests also showed an improvement in some brain function.
Read More at http://www.bbc.co.uk/news/health-16945466.
On Monday, The Lancet medical journal published a paper on trials at UCLA in which hESC-derived cells were transplanted into human patients, with positive results for sufferers of macular degeneration. Parallel trials are currently taking place in the UK at Moorfields Eye Hospital in London.
Macular degeneration is also a target of SENS Foundation research.
Read More at http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2960028-2/ab....
The Mayo Clinic has recently published exciting results from an independent research project it conducted with collaborators at the University of Groningen in the journal Nature. The project successfully demonstrated that the clearance of senescent cells can delay the onset of adverse age-related changes, such as muscle loss, in mice that have been genetically engineered to age at an increased rate. This represents the finest proof of concept work to date on the effectiveness of senescent cell removal in countering the effects of aging. You can see the publication here, the Mayo Clinic's press release here, and can read coverage from the Wall Street Journal, the New York Times, and CBS News.
SENS Foundation has long supported the theory that the removal of senescent cells can contribute to increased health in old age (our own approach is outlined here). In fact, the prospective treatment suggested by the Clinic’s research is a rejuvenation biotechnology, an application of regenerative medicine to the diseases of aging. Senescent cells represent one of the several types of damage that accumulate with age -- one of the several types of damage that rejuvenation biotechnologies might repair.
The strength of this damage-repair approach is reflected in senior author Dr. van Deursen’s sentiment (reported by the Wall Street Journal) that the clearance of senescent cells might allow multiple diseases of aging to be treated as a group. This is a statement that we entirely agree with. If the many diseases of aging are, as we believe, ultimately caused by damage that falls into only a handful of categories -- seven by our best count -- dealing comprehensively with one type of damage can counter several, if not many, diseases. With luck, the Clinic’s clear demonstration of the effectiveness of this approach will encourage other researchers to work towards the development of rejuvenation biotechnologies.
A side note: we had the pleasure of having two of this paper’s authors, Drs. Kirkland and LeBrasseur, give presentations at our recent SENS5 conference. Videos of their talks have been posted on SENS Foundation's Youtube channel: you can view Dr. Kirkland's here and Dr. LeBrasseur's here.
Read More at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature10600.html.
SENS Foundation's CSO's has submitted a fresh introductory overview and status update of SENS, as part of a series of covering the various fundamental aspects of age-related infirmity.Read More at http://www.huffingtonpost.com/aubrey-de-grey-phd/age-related-diseases_b_985019.h....
For more information on our titular collaborators, see .Read More at http://www2.journalnow.com/business/2011/jun/03/wsbiz01-regenerative-medicine-in....
Good article, and interesting comments after the first few lines of bickering.
Scientists in the United States have managed to turn human embryonic stem cells into a type of brain cell linked to memory loss in Alzheimer's disease. The research, published in the journal Stem Cells, should help in the development and testing of potential new medicines to treat the neurodegenerative disease which affects around half a million people in the UK.
Fergus Walsh is the only journalist I could find to write carefully on this.
I heartily agree with the following paragraph.
I confess I worry about the phrases "major breakthrough" and "major step forward". For me, the former should be reserved for something which is a game-changing piece of research, or a new device or treatment which transforms the way we combat a condition. Like many things it's hard to describe, but you know it when you see it. "Major step forward" is problematic unless you also know how many steps there are left to travel on a journey.
Read More at http://www.bbc.co.uk/blogs/thereporters/ferguswalsh/2011/03/lab-grown_brain_cell....
The dismal odds of winning an NIA-funded grant "threaten the viability of ageing research" says Richard Hodes, the NIA's director. "If we are less able to fund research — or are perceived to be less able — that will actually drive young and emerging investigators to fields other than ageing. That would be a catastrophe at a time when such research is critically important."
Read More at http://www.nature.com/news/2010/101110/full/468148a.html.
Our CSO Aubrey de Grey partakes in an interesting debate concerning the theoretical consequences of radical life extension. The debate is way up high on the ivory tower, but worth a listen.
Read More at http://www.scpr.org/programs/patt-morrison/2010/11/09/16779/dodging-death-is-rad....
El Ser Creativo, to be held in Málaga on October 21st-23rd, is focused on great ideas and ways of sharing them. Dr Aubrey de Grey is one of the 25 speakers who will present and answer questions on their work and ideas, and their implications for society.
The World Congress on Preventive & Regenerative Medicine, hosted this year in Hannover from October 5th-7th, is the only international event addressing the entire regenerative medicine sector. This broad remit, similar to that of the SENS conference series, gives the meeting outstanding potential to foster interdisciplinary collaborations in research and development.
Dr de Grey is a vice-president of the Congress, and will co-chair a session entitled "Rejuvenation Biotechnologies: Applying Regenerative Medicine to Aging".Read More at http://www.regmed.org/.